Patient demographics and baseline characteristics*
| Characteristic | All treated patients N=50 | Progressed on prior anti-PD-1 therapy n=33 | No prior anti-PD-1 therapy n=17 |
| Age, median (range), year | 64.5 (28‒88) | 65.0 (28‒84) | 64.0 (35‒88) |
| Sex | |||
| Men | 31 (62) | 22 (67) | 9 (53) |
| Women | 19 (38) | 11 (33) | 8 (47) |
| White | 50 (100) | 33 (100) | 17 (100) |
| ECOG PS | |||
| 0 | 34 (68) | 21 (64) | 13 (76) |
| 1 | 16 (32) | 12 (36) | 4 (24) |
| Stage | |||
| III | 14 (28) | 7 (21) | 7 (41) |
| IVM1a | 7 (14) | 4 (12) | 3 (18) |
| IVM1b | 6 (12) | 4 (12) | 2 (12) |
| IVM1c(1)† | 12 (24) | 11 (33) | 1 (6) |
| IVM1c(2)‡ | 11 (22) | 7 (21) | 4 (24) |
| Baseline tumor burden, median (range), mm2 | 1479 (209‒18,218) | 1425 (225‒18,218) | 2750 (209‒7348) |
| BRAF mutation status | |||
| Mutant | 17 (34) | 12 (36) | 5 (29) |
| Wild-type | 26 (52) | 18 (55) | 8 (47) |
| Unknown | 7 (14) | 3 (9) | 4 (24) |
| Received any prior systemic therapy | 40 (80) | 33 (100) | 7 (41) |
| 1 line | 16 (32) | 10 (30) | 6 (35) |
| 2 lines | 8 (16) | 8 (24) | 0 |
| ≥3 lines | 16 (32) | 15 (45) | 1 (6) |
| Select prior pharmacologic therapy§ | |||
| Chemotherapy | 8 (16) | 7 (21) | 1 (6) |
| Hormone therapy | 1 (2) | 1 (3) | 0 |
| Immunotherapy | 29 (58) | 27 (82) | 2 (12) |
| Targeted therapy | 4 (8) | 4 (12) | 0 |
*Data are presented as n (%), unless otherwise noted.
†Metastases to all other visceral metastases with a normal lactate dehydrogenase.
‡Any distant metastases with an elevated lactate dehydrogenase.
§Patients could have been counted in more than one row.
anti-PD-1, anti-programmed death 1; ECOG PS, Eastern Cooperative Oncology Group performance status.